In patients with severe RA, refractory to conventional disease-modifying antirheumatic drug (DMARD) therapy, periodical treatment with infliximab (an anti-TNFα blocker) results in a rapid reduction of serum resistin levels [47]. This evidence concerns the gene RETN and rheumatoid arthritis.